Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting SIRT1 in esophageal cancer

xlomafota13 shared this article with you from Inoreader Rapamycin suppresses the PI3K/AKT/mTOR signaling pathway by targeting <em>SIRT1</em> in esophageal cancer Via Experimental and therapeutic medicine Exp Ther Med. 2021 Oct;22(4):1190. doi: 10.3892/etm.2021.10624. Epub 2021 Aug 17. ABSTRACT Rapamycin, a secondary metabolite produced by Streptomyces hygroscopicus, is known for its pharmacological effects, especially antitumor and immunosuppressive activities. However, the antitumoral effects of rapamycin in human esophageal cancer (EC) are still poorly understood. To investigate the potential of rapamycin in EC treatment, sirtuin 1 (SIRT1) mRNA expression was quantified in the tissue of patients with EC or in EC cell lines using reverse transcription-quantitative PCR. The protein levels of SIRT1 and PI3K/AKT/mTOR were measured via western blotting. Furthermore, cell viability, migration and invasion were investigated by Cell Counting Kit-8, wound healing and Transwell assays, respectively. The present results suggested that SIRT1 expression was upregulated in EC. In vitro, the inhibitory effect of r apamycin on cell viability in EC was strengthened or weakened after small interfering (si)-SIRT1 or pcDNA3.1/SIRT1 transfection. Furthermore, SIRT1 rescued the inhibitory effect of rapamycin on the migration and invasion of EC cells. In vivo, si-SIRT1 or SIRT1 overexpression in mice could enhance or rescue the inhibitory effects of rapamycin on tumor growth. In addition, SIRT1 transfection rescued the decreased level of phosphorylated (p)-PI3K, p-AKT and p-mTOR induced by rapamycin treatment. Taken together, the present results suggested that rapamycin suppressed the cell viability, migration, invasion and PI3K/AKT/mTOR signaling pathway in EC by negatively regulating SIRT1. PMID:34475980 | PMC:PMC8406672 | DOI:10.3892/etm.2021.10624 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

The differential expression of perilipin-2 in hepatoblastoma and its association with prognosis

xlomafota13 shared this article with you from Inoreader The differential expression of perilipin-2 in hepatoblastoma and its association with prognosis Via Cellular and Molecular Biology Histol Histopathol. 2021 Sep 3:18371. doi: 10.14670/HH-18-371. Online ahead of print. ABSTRACT Perilipin-2, a lipid droplet (LD) coating protein, has been found to be involved in cancer progression. However, its role in hepatoblastoma (HB) is undefined. We collected 87 HB samples and the corresponding clinical data. Immunohistochemistry (IHC) staining was performed to detect perilipin-2 and the association of the perilipin-2 expression with clinical characteristics and prognosis was analyzed. The expression of perilipin-2 was increased in fetal HB components in comparison to embryonal HB components. The predominant staining pattern was vesicular in fetal HB cells, while it was granular in embryonal HB cells. Furthermore, strong expression of perilipin-2 was associated with the histopathological type of fetal predominant HB. Although event-free survival (EFS) did not differ to a statistically significant extent between the strong and we ak expression groups in a univariate survival analysis, a multivariate survival analysis revealed that EFS was significantly improved in the strong perilipin-2 expression group. In conclusion, perilipin-2 is differentially expressed in HB and the strong expression of perilipin-2 predicts a better prognosis. PMID:34477212 | DOI:10.14670/HH-18-371 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Speech pathology service enhancement for people with head and neck cancer living in rural areas: Using a concept mapping approach to inform service change

xlomafota13 shared this article with you from Inoreader Speech pathology service enhancement for people with head and neck cancer living in rural areas: Using a concept mapping approach to inform service change Via Head & Neck Abstract Background Speech pathology (SP) services provide swallowing and communication intervention to people with head and neck cancer (HNC) across the continuum of care. However, difficulties exist with access and delivery of services in rural areas. The study aim was to identify actionable goals for SP change, utilizing a concept mapping approach. Methods Eleven SP staff from two regional/remote services completed the concept mapping process. Multivariate analysis and multidimensional scaling were used to develop a final set of prioritized goals for change. Results Between the two participating health services, 30 actionable goals were identified within the "green-zone" on the go-zone graph of importance and changeability. Among the most highly rated areas for change was the need to deliver and receive more support for training, mentoring, and supervision to consolidate skills. Conclusions This methodology enabled identification of prioritized, actionable changes to improve SP services for people with HNC living in regional/remote areas. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Hyperspectral imaging and artificial intelligence to detect oral malignancy – part 1 - automated tissue classification of oral muscle, fat and mucosa using a light-weight 6-layer deep neural network

xlomafota13 shared this article with you from Inoreader Hyperspectral imaging and artificial intelligence to detect oral malignancy – part 1 - automated tissue classification of oral muscle, fat and mucosa using a light-weight 6-layer deep neural network Via Head & Face Medicine Hyperspectral imaging (HSI) is a promising non-contact approach to tissue diagnostics, generating large amounts of raw data for whose processing computer vision (i.e. deep learning) is particularly suitable. A... View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

A retrospective study of 44 patients with head and neck Castleman's disease

xlomafota13 shared this article with you from Inoreader A retrospective study of 44 patients with head and neck Castleman's disease Via http://link.springer.com/journal/405,European archives of oto-rhino-laryngology,The European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino Eur Arch Otorhinolaryngol. 2021 Sep 4. doi: 10.1007/s00405-021-07065-0. Online ahead of print. ABSTRACT PURPOSE: To explore the clinical and pathological features, therapy and prognosis of Castleman's disease (CD) in the head and neck. METHODS: We retrospectively analyzed the clinical and pathological data of 44 patients with head and neck CD who were diagnosed in the Fujian Medical University Union hospital (Fujian, China) between May 2008 and June 2021. According to the clinical classification, they were divided into two groups, the unicentric CD (UCD, n = 20) and the multicentric CD (MCD, n = 24). Their clinical features, imaging findings, laboratory examination, and treatment results were, respectively, analyzed. RESULTS: The age of UCD patients was younger than that of MCD patients. Most of the UCD patients (80%) were female, with asymptomatic single lymphadenectasis, and the prognosis was favorable; while 70.8% of the MCD patients were male, with multiple lymph nodes throughout the body, and more prone to hepatosplenomegaly, pneumonia, serous effusion, anemia, hypoalbuminemia, elevated globulin, coagulation disorders, etc., the prognosis was bleak. Two cases of MCD patients were with systemic lupus erythematosus (SLE). CONCLUSIONS: UCD usually manifests as asymptomatic single lymph node enlargement, complete surgical resection was the mainstay of treatment modality. MCD has relatively complicated clinical symptoms and poor prognosis, and anti-IL-6 therapy may be effective. PMID:34480599 | DOI:10.1007/s00405-021-07065-0< /p> View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

Type 4 persistent primitive olfactory artery associated with contralateral accessory middle cerebral artery arising from the fenestrated segment of the distal anterior cerebral artery

xlomafota13 shared this article with you from Inoreader Type 4 persistent primitive olfactory artery associated with contralateral accessory middle cerebral artery arising from the fenestrated segment of the distal anterior cerebral artery Via radiol anat Surg Radiol Anat. 2021 Sep 4. doi: 10.1007/s00276-021-02831-5. Online ahead of print. ABSTRACT Persistent primitive olfactory artery (PPOA) is a rare variation of the proximal anterior cerebral artery (ACA) that generally follows an extreme anteroinferior course and takes a hairpin turn before continuing to the A2 segment of the ACA (type 1). There are four other types of extremely rare variations. The type 4 variation continues to the accessory middle cerebral artery (MCA) instead of the ACA. Only a few cases have been reported. We herein report a case of type 4 PPOA in which the contralateral side of the accessory MCA arose from the fenestrated segment of the distal ACA. No similar cases were found in the relevant English-language literature. For the identification of these variations on MR angiography, volume-rendering images were superior to maximum-intensity-projection images. PMID:34480592 | DOI:10.1007/s00276-021-02831-5 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.

(−)-Epigallocatechin-3-gallate (EGCG) prevents aminoglycosides-induced ototoxicity via anti-oxidative and anti-apoptotic pathways

xlomafota13 shared this article with you from Inoreader (−)-Epigallocatechin-3-gallate (EGCG) prevents aminoglycosides-induced ototoxicity via anti-oxidative and anti-apoptotic pathways Via International Journal of Pediatric Otorhinolaryngology Publication date: Available online 4 September 2021 Source: International Journal of Pediatric Otorhinolaryngology Author(s): Yulong Zong, Fang Chen, Shanshan Li, Hui Zhang View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.